Atypical antipsychotics in the treatment of mood disorders

Current Opinion in Psychiatry

Volumn 20, Issue 1, 2007, Pages 23-29

  Jarema, Marek ^a  

^a INSTITUTE OF PSYCHIATRY AND NEUROLOGY   (Poland)

Author keywords

Atypical antipsychotics; Bipolar disorder; Depression; Mania

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CITALOPRAM; FLUOXETINE; LITHIUM; OLANZAPINE; QUETIAPINE; RISPERIDONE; VALPROIC ACID; ZIPRASIDONE; ZOTEPINE;

AGITATION; AKATHISIA; AUTONOMIC DYSFUNCTION; BIPOLAR DISORDER; DEPRESSION; DIZZINESS; DRUG USE; EVALUATION; EXTRAPYRAMIDAL SYMPTOM; HEADACHE; HUMAN; INSOMNIA; MANIA; METABOLIC SYNDROME X; MOOD DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; PAIN; RELAPSE; REVIEW; SIDE EFFECT; SOMNOLENCE; SYMPTOMATOLOGY; TREMOR; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DEPRESSIVE DISORDER, MAJOR; HUMANS; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 33845421095     PISSN: 09517367     EISSN: None     Source Type: Journal    
DOI: 10.1097/YCO.0b013e328010e29b     Document Type: Review

References (61)

1. Kapur S, Mamo D. Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27:1081-1090.
2. Post RM, Calabrese JR. Bipolar depression: the role of atypical antipsychotics. Exp Rev Neurother 2004; 14:S27-S33.
3. Ghaemi SN, Hsu DJ, Rosenquist KJ, et al. Extrapyramidal side effects with atypical neuroleptics in bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30:209-213.
4. Svestka J. Treatment of bipolar depression. In: Jarema M, Hotujac L, Oral ET, et al. Treatment of bipolar disorders with second generation antipsychotic medications. Neuroendocrinol Lett 2005;26 (Suppl 1):27-48. A comprehensive review of the use of atypical antipsychotic in the treatment of depression includes monotherapy and add-on studies.
5. Masan PS. Atypical antipsychotics in the treatment of affective symptoms: a review. Ann Clin Psychiatry 2004; 16:3-13.
6. Bowden CL. Atypical antipsychotic augmentation of mood stabilizer therapy in bipolar disorder. J Clin Psychiatry 2005; 66 (Suppl 30):12-19.
7. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002;159(Suppl 4):1-50.
8. Montgomery SA. Dopaminergic deficit and the role of amisulpride in the treatment of mood disorders. Int Clin Psychopharmacol 2002; 17 (Suppl 4):S9-S15.
9. Sachs G, Sanchez R, Marcus R, et al. Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study. J Psychopharmacol 2006; 20:536-546.
10. Möller HJ. Antipsychotic and antidepressive effects of second generation antipsychotics. Eur Arch Psychiatry Clin Neurosci 2005; 255:190-201. This article gives a general review of the usefulness of the antipsychotics in depression and underlines the background of depressive symptomatology.
11. Simon JS, Nemeroff CB. Aripiprazole augmentation of antidepressants for the treatment of partially responding and nonresponding patients with major depressive disorder. J Clin Psychiatry 2005; 66:1216-1220.
12. Papakostas GI, Petersen TJ, Kinrys G, et al. Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder. J Clin Psychiatry 2005; 66:1326-1330.
13. Mathews J, Garcia KS, Mintun MA, Sheline YI. Antidepressant efficacy of olanzapine as monotherapy in major depressive disorder, without psychosis: a pilot study. Psychiatry Res 2006; 146:149-155.
14. Shelton RC. Olanzapine/fluoxetine combination for bipolar depression. Expert Rev Neurother 2006; 6:33-39.
15. Corya SA, Williamson D, Sanger TM, et al. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression. Depress Anxiety 2006; 1:1-9.
16. Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003; 60:1079-1088.
17. Shelton RC, Tollefson GD, Tohen M, et al. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry 2001; 158:131-134.
18. Dando TM, Keating GM. Spotlight on quetiapine in acute mania and depression associated with bipolar disorder. CNS Drugs 2006; 20:429-431.
19. Pini S, Abelli M, Cassano GB. The role of quetiapine in the treatment of bipolar disorder. Expert Opin Pharmacol 2006; 7:929-940.
20. Sajatovic M, Mullen JA, Sweitzer DE. Efficacy of quetiapine and risperidone against depressive symptoms in outpatients with psychosis. J Clin Psychiatry 2002; 63:1156-1163.
21. Calabrese J, Macfadden W, McCoy R, et al. Double-blind, placebo-controlled study of quetiapine in bipolar depression. Presented at the 157th Annual Meeting of the American Psychiatric Association; 1-6 May 2004; New York, NY.
22. Macfadden W, Spong E, Minkwitz M, et al. Analysis of suicidality in patients with bipolar depression treated with quetiapine monotherapy. Presented at the XXVth Biennial CINP Congress; 9-13 July 2006; Chicago.
23. Parker G, Malhi G. Are atypical antipsychotic drugs as atypical antidepressants? Aust N Z J Psychiatry 2001; 35:631-638.
24. Vieta E, Gasto C, Colom F, et al. Role of risperidone in bipolar II: an open 6-month study. J Affect Disord 2001; 67:213-219.
25. Stahl S, Shelton RC. Risperidone with and without paroxetine compared to paroxetine alone for bipolar depression. Presented at the 40th Annual Meeting of American College of Neuropsychopharmacology; 9-13 December 2001; Waikoloa.
26. McIntyre RS, Mancini DA, Srinivasan J, et al. The antidepressant effects of risperidone and olanzapine in bipolar disorder. Can J Clin Psychiatry 2004; 11:218-226.
27. Barbee JG, Conrad EJ, Jamhour NJ. The effectiveness of olanzapine, risperidone, quetiapine, and ziprasidone as augmentation agents in treatment-resistant major depressive disorder. J Clin Psychiatry 2004; 65:975-981.
28. Goto M, Yoshimura R, Kakihara S, et al. Risperidone in the treatment of psychotic depression. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30:701-707.
29. Rapaport MH, Gharabawi GM, Canuso CM, et al. Effects of risperidone augmentation in patients with treatment-resistant depression: results of open-label treatment followed by double-blind continuation. Neuropsychopharmacology, 7 June 2006 [E-pub ahead of print].
30. Kennedy SH, Lam RW. Enhancing outcomes in the management of treatment resistant depression: a focus on atypical antipsychotics. Bipolar Disord 2003; 5 (Suppl 2):36-47.
31. Weisler R, Warrington L, Dunn J, et al. Adjunctive ziprasidone in bipolar mania: short- and long-term data. Presented at the 157th Annual Meeting of the American Psychiatric Association; 1-6 May 2004; New York.
32. Gunasekara NS, Spencer CM, Keating GM. Spotlight on ziprasidone in schizophrenia and schizoaffective disorder. CNS Drugs 2002; 16:645-652.
33. Nemeroff CB. Use of atypical antipsychotics in refractory depression and anxiety. J Clin Psychiatry 2005; 66 (Suppl 8):13-21. The possible advantage of the use of atypical antipsychotics in patients resistant to treatment is discussed.
34. Papakostas GI, Petersen TJ, Nierenberg AA, et al. Ziprasidone augmentation of selective serotonin reuptake inhibitors (Saris) for SSRI-resistant major depressive disorder. J Clin Psychiatry 2004; 65:217-221.
35. Potkin SG, Keck PE, Segal S, et al. Ziprasidone in acute bipolar mania: a 21-day randomized, double-blind, placebo-controlled replication trial. J Clin Psychiatry 2005; 25:301-310.
36. Perlis RH, Welge JA, Vornik LA, et al. Atypical antipsychotics in the treatment of mania: a meta-analysis of randomized, placebo-controlled trials. J Clin Psychiatry 2006; 67:509-516. This is a review paper that discusses the meta-analysis of the potential usefulness of atypical antipsychotics in manic states.
37. Chengappa KN, Suppes T, Berk M. Treatment of bipolar mania with atypical antipsychotics. Expert Rev Neurother 2004; 4:S17-S25.
38. Rachid F, Bertschy G, Bondolfi G, et al. Possible induction of mania or hypomania by atypical antipsychotics: an updated review of reported cases. J Clin Psychiatry 2004; 65:1537-1545.
39. Vieta E, Ros S, Goikolea JM, et al. An open-label study of amisulpride in the treatment of mania. J Clin Psychiatry 2005; 66:575-578.
40. Sachs G, Sanchez R, Marcus R, et al. Aripirazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study. J Psychopharmacol 2006; 24:536-546.
41. Keck PE Jr, Calabrese JB, McQuade RD, et al. A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J Clin Psychiatry 2006; 67:626-637.
42. Lieberman DZ, Goodwin FK. Use of olanzapine in the treatment of bipolar I disorder. Expert Rev Neurother 2004; 4:759-767.
43. McCoormack PL, Wiseman LR. Spotlight on olanzapine in bipolar I disorder. CNS Drugs 2005; 19:553-555. This article evaluates the usefulness of olanzapine in bipolar patients.
44. Jones RM, Thompson C, Bitter I. A systematic review of the efficacy and safety of second generation antipsychotics in the treatment of mania. Eur Psychiatry 2006; 21:1-9. This article gives a comprehensive and systematic review of the use of atypical antipsychotics in manic states and describes the use of each drug in detail.
45. Rendell JM, Gijsman HJ, Keck P, et al. Olanzapine alone or in combination for acute mania. Cochrane Database Syst Rev 2003:CD004040.
46. Hennen J, Perlis RH, Sachs G, et al. Weight gain during treatment of bipolar I patients with olanzapine. J Clin Psychiatry 2004; 65:1679-1687.
47. Shi L, Juarez R, Hackworth J, et al. Open-label olanzapine in bipolar I disorder: clinical and work functional outcomes. Curr Med Res Opin 2006; 22:961-966.
48. Sajatovic M, Brescan DW, Perez DE, et al. Quetiapine alone and added to a mood stabilizer for serious mood disorders. J Clin Psychiatry 2001; 62:728-732.
49. Dando TM, Keating GM. Spotlight on quetiapine in acute mania and depression associated with bipolar disorder. CNS Drugs 2006; 20:429-431.
50. Pini S, Abelli M, Cassano GB. The role of quetiapine in the treatment of bipolar disorder. Expert Opin Pharmacother 2006; 7:929-940.
51. Sachs G, Chengappa KNR, Suppes T, et al. Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomized, double-blind, placebo-controlled study. Bipolar Disord 2004; 6:213-223.
52. Lakshmi NY, Paulsson B, Mullen J, et al. Quetiapine versus placebo in combination with lithium or divalproex for the treatment of bipolar mania. J Clin Psychopharmacol 2004; 24:599-606.
53. Hatim A, Habil H, Jesjeet SG, et al. Safety and efficacy of rapid dose administration of quetiapine in bipolar mania. Hum Psychopharmacol 2006; 20:313-318. The paper shows the possibility of the use of quetiapine in rapid escalated doses instead of the slow dose increase.
54. Rendell JM, Gijsman HJ, Bauer MS, et al. Risperidone alone or in combination for acute mania. Cochrane Database Syst Rev 2006:CD004043. This study presents a general view of the possibilities of the risperidone treatment of manic states.
55. Nguyen LN, Guthrie SK. Risperidone treatment of bipolar mania. Ann Pharmacother 2006; 40:674-782.
56. Tsai JH, Tang TC, Yang P, et al. Adjunctive treatment of acute mania with risperidone versus typical antipsychotics: a retrospective study. Kaohjung J Med Sci 2005; 21:539-544.
57. Keck PE, Versiani M, Potkin S, et al. Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. Am J Psychiatry 2003; 160:741-748.
58. Keck PE, Potkin SG, Rappard, et al. Efficacy and safety of ziprasidone in bipolar disorder: short- and long-term data. Presented at the XXV CUNP Congress; 9-13 July 2006; Chicago.
59. Stahl S, Lombardo I, Loebl A, et al. Efficacy of ziprasidone in dysphoric mania: pooled analysis of two double-blind studies. Presented at the XXV CUNP Congress; 9-13 July 2006; Chicago.
60. Amann B, Sterr A, Mergl R, et al. Zotepine loading in acute and severely manic patients: a pilot study. Bipolar Disord 2005; 7:471-476.
61. Oral ET. Treatment of acute mania. In: Jarema M, Hotujac L, Oral ET, et al. Treatment of bipolar disorders with second generation antipsychotic medications. Neuroendocrinol Lett 2005;26 (Suppl 1):9-25. This article provides a comprehensive and detailed view of the utility of atypical drugs in mania and describes the use of each drug separately.